Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Retevmo

(reh-TEV-moh)
A drug used to treat certain types of non-small cell lung cancer in adults and certain types of thyroid cancer or other solid tumor in adults and children aged 2 years and older. It is used in patients whose cancer has an abnormal RET gene. It is also being studied in the treatment of other types of cancer. Retevmo blocks certain proteins, including those made by the RET fusion gene or the mutated RET gene. Blocking these proteins may help keep cancer cells from growing. Retevmo is a type of tyrosine kinase inhibitor. Also called selpercatinib.
More Information
Search NCI's Dictionary of Cancer Terms